Back to Search
Start Over
Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma.
- Source :
- Cancer Nanotechnology (1868-6958); 7/2/2024, Vol. 15 Issue 1, p1-13, 13p
- Publication Year :
- 2024
-
Abstract
- Background: Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. Methods: Here, we investigated the potential of small extracellular vesicle (sEV) microRNAs (miRNAs) as predictive biomarkers for anlotinib efficacy. A total of 20 advanced NSCLC patients were enrolled. Patients were classified as having stable disease (SD) or progressive disease (PD) after the initial efficacy assessment. Results: Seven differentially expressed miRNAs (DEMs) were identified. Among them, miR-941 was significantly upregulated in the PD group, while the others were downregulated. Furthermore, these six downregulated miRNAs (miR-30a-3p, miR-150-5p, miR-122-5p, miR-10b-5p, miR-92a-3p, and miR-150-3p) were more pronounced in nonsmoking patients. Conclusions: It was found that sEV miRNAs have the potential to predict the benefit of anlotinib. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 18686958
- Volume :
- 15
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Cancer Nanotechnology (1868-6958)
- Publication Type :
- Academic Journal
- Accession number :
- 178231976
- Full Text :
- https://doi.org/10.1186/s12645-024-00273-3